MGI boost for Eisai, but lansoprazole languishes
This article was originally published in Scrip
Executive Summary
Eisaiwas keen to stress at its first quarter results briefing the positive effect that its acquisition of MGI Pharma was already having, pointing out that the move had already boosted sales of oncology products to 10% of the consolidated total in the first quarter, compared with less than 2% last year.